Compare Summit Therapeutics Inc (SMMT) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Tapestry, Inc. — how do they compare? Summit Therapeutics Inc trades at $17.58 (market cap $13.79B), while Tapestry, Inc. trades at $114.76 (market cap $23.44B). The key difference: Tapestry, Inc. is the larger of the two by market cap, and Tapestry, Inc. pays a 1.57% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TPR | |
|---|---|---|
Market Cap | $13.79B | $23.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $164.78 |
52-Week Low | $12.43 | $98.81 |
Enterprise Value | $13.11B | $26.25B |
Dividend Yield | — | 1.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
TPR trades at $117.58, down 3.73% amid bearish technical signals, though oversold RSI readings suggest potential near-term support. The company maintains strong profitability with 77.82% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights international growth acceleration in China and Europe, while analyst consensus remains strongly bullish with a $182.44 price target representing 55% upside potential.
The stock presents a compelling value opportunity given the disconnect between strong fundamentals and recent price weakness. Key catalysts include continued international expansion and margin improvement targets, though risks include Kate Spade execution challenges, tariff pressures, and premium valuation multiples that may limit near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
